JP2019507111A5 - - Google Patents

Download PDF

Info

Publication number
JP2019507111A5
JP2019507111A5 JP2018532741A JP2018532741A JP2019507111A5 JP 2019507111 A5 JP2019507111 A5 JP 2019507111A5 JP 2018532741 A JP2018532741 A JP 2018532741A JP 2018532741 A JP2018532741 A JP 2018532741A JP 2019507111 A5 JP2019507111 A5 JP 2019507111A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
heteroaryl
aryl
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019507111A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/067852 external-priority patent/WO2017112701A1/en
Publication of JP2019507111A publication Critical patent/JP2019507111A/ja
Publication of JP2019507111A5 publication Critical patent/JP2019507111A5/ja
Pending legal-status Critical Current

Links

JP2018532741A 2015-12-22 2016-12-20 代謝抵抗性フェンフルラミン類縁体およびその使用法 Pending JP2019507111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562271168P 2015-12-22 2015-12-22
US62/271,168 2015-12-22
PCT/US2016/067852 WO2017112701A1 (en) 2015-12-22 2016-12-20 Metabolism resistant fenfluramine analogs and methods of using the same

Publications (2)

Publication Number Publication Date
JP2019507111A JP2019507111A (ja) 2019-03-14
JP2019507111A5 true JP2019507111A5 (enExample) 2020-01-30

Family

ID=59065966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532741A Pending JP2019507111A (ja) 2015-12-22 2016-12-20 代謝抵抗性フェンフルラミン類縁体およびその使用法

Country Status (7)

Country Link
US (4) US10689324B2 (enExample)
EP (1) EP3393470B1 (enExample)
JP (1) JP2019507111A (enExample)
KR (1) KR20180095674A (enExample)
AU (1) AU2016379345B2 (enExample)
CA (1) CA3007673A1 (enExample)
WO (1) WO2017112701A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
HUE053114T2 (hu) 2015-12-22 2021-06-28 Zogenix International Ltd Fenfluramin kompozíciók és eljárások azok elõállítására
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
CA3132318A1 (en) * 2019-03-01 2020-09-10 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of obesity and related disorders
JP7629678B2 (ja) * 2019-03-01 2025-02-14 アブレキサ ファーマスーティカルズ,インコーポレイテッド 術後認知機能障害の予防及び治療のための化合物
KR20220015413A (ko) * 2019-05-29 2022-02-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 간질을 치료하기 위한 방법 및 조성물
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
WO2023028092A2 (en) * 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Fluorinated empathogens
WO2023101866A1 (en) * 2021-12-01 2023-06-08 Zogenix International Limited Fenfluramine for treatment of conditions associated with spreading depolarization
WO2026013310A1 (en) * 2024-07-11 2026-01-15 Biocodex Liquid pharmaceutical composition based on stiripentol

Family Cites Families (138)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL270984A (enExample) 1960-11-05
US3117160A (en) * 1961-07-27 1964-01-07 Pfizer & Co C Aralkylamines
US3198834A (en) 1964-07-27 1965-08-03 Snc Science Union Et Compagnie Optical isomers of trifluoromethylated phenethylamines
GB1254332A (en) * 1969-02-27 1971-11-17 Science Union & Cie Amino acids and their derivatives and processes for preparing them
DE2143204C3 (de) * 1971-08-28 1979-09-27 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis
DE2150399A1 (de) 1971-10-09 1973-04-12 Hoechst Ag Neue oxime
GB1413078A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof
GB1413070A (en) 1973-07-27 1975-11-05 Beecham Group Ltd Process for the production of - norfenfluramine and - fenfluramine and salts thereof
US4309445A (en) 1980-06-16 1982-01-05 Massachusetts Institute Of Technology d-Fenfluramine for modifying feeding behavior
US4452815A (en) 1980-06-16 1984-06-05 Massachusetts Institute Of Technology Method of utilizing d,l-fenfluramine for modifying feeding behavior
DE3717434C1 (de) 1987-05-23 1988-09-15 Degussa Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
KR890003368A (ko) 1987-08-06 1989-04-14 원본미기재 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법
HU204497B (en) 1989-10-09 1992-01-28 Chinoin Gyogyszer Es Vegyeszet Process for producing phenfluramine
IT1238686B (it) 1990-02-09 1993-09-01 Lab Mag Spa Procedimento per la preparazione di levo e destro fenfluramina
FR2684552B1 (fr) 1991-12-06 1995-04-28 Adir Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants.
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
DE69422044T2 (de) 1993-08-06 2000-05-31 Pharmacia & Upjohn Co., Kalamazoo 2-aminoindane als selektive dopamin-d3-liganden
US5834477A (en) 1993-12-08 1998-11-10 The United States Of America As Represented By The Secretary Of The Army Opiate analgesic formulation with improved safety
US5412102A (en) 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
ATE199829T1 (de) 1994-06-03 2001-04-15 Thejmde Trust Meta substituierte arylalkylamine und therapeutische und diagnostische verwendung davon
IT1298349B1 (it) 1996-05-29 2000-01-05 Alfa Chem Ital Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina
IT1292885B1 (it) 1997-04-28 1999-02-11 Alfa Chem Ital Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina.
EP0920864A1 (en) 1997-12-03 1999-06-09 Pfizer Products Inc. Combination therapy including a specific beta-3 agonist and an anorectic agent
US20020098175A1 (en) 1998-06-16 2002-07-25 Zohoungbogbo Mathias C. Dietetic food composition and dietetic method using such composition
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6472431B2 (en) 1998-12-23 2002-10-29 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7124031B1 (en) 2000-05-11 2006-10-17 Medco Health Solutions, Inc. System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records
US20020032581A1 (en) 2000-07-17 2002-03-14 Reitberg Donald P. Single-patient drug trials used with accumulated database: risk of habituation
US6315720B1 (en) 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Pharmaceuticals, Inc. Delivery of drug esters through an inhalation route
CA2449613A1 (en) 2001-06-22 2003-01-03 Universite Catholique De Louvain Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids
CA2455939C (en) 2001-07-31 2011-03-22 Wyeth Llc Sucralose formulations to mask unpleasant tastes
AUPR732601A0 (en) 2001-08-28 2001-09-20 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of amines such as ephedrine and inter mediates
BR0212985A (pt) 2001-09-24 2005-08-30 Imp College Innovations Ltd Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
RU2317104C2 (ru) 2001-09-24 2008-02-20 Импиэриэл Инноувейшнс Лимитид Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
US6599901B1 (en) 2001-11-19 2003-07-29 Hoffman-La Roche Inc. Pyridone substituted benzothiazole derivatives
US7101572B2 (en) 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
JP3813152B2 (ja) 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
AU2003225964B2 (en) 2002-03-28 2008-11-20 Merck Sharp & Dohme Corp. Substituted 2,3-diphenyl pyridines
US7668730B2 (en) 2002-12-17 2010-02-23 JPI Commercial, LLC. Sensitive drug distribution system and method
WO2005004865A1 (en) 2003-07-08 2005-01-20 Georg-August-Universität Göttingen Use of 5-ht4(a)-serotonin receptor agonists
GB0410266D0 (en) 2004-05-07 2004-06-09 Ketocytonyx Inc Treatment of apoptosis
US20050260610A1 (en) 2004-05-20 2005-11-24 Kurtz Richard E Method for diagnosing and prescribing a regimen of therapy for human health risk
US9820658B2 (en) 2006-06-30 2017-11-21 Bao Q. Tran Systems and methods for providing interoperability among healthcare devices
US20090216132A1 (en) 2005-03-21 2009-08-27 Tuvi Orbach System for Continuous Blood Pressure Monitoring
RU2007148444A (ru) 2005-05-25 2009-06-27 Янссен Фармацевтика Н.В. (Be) Педиатрическая композиция топирамата
EP1904630A4 (en) 2005-06-16 2009-10-21 Bionomics Ltd METHODS OF TREATING AND DIAGNOSING EPILEPSY BY DETECTING MUTATIONS OF THE SCN1A GENE
GB0515090D0 (en) 2005-07-22 2005-08-31 Birmingham Res & Dev Ltd Novel epilepsy treatment
WO2007031846A2 (en) 2005-09-14 2007-03-22 University Of The Witwatersrand, Johannesburg Pharmaceutical composition
CA2622967A1 (en) 2005-09-19 2007-03-29 Biolert Ltd. A system and method for detecting an epileptic event
EP3223182A1 (en) 2005-11-29 2017-09-27 Children's Hospital Medical Center Optimization and individualization of medication selection and dosing
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2007079181A2 (en) 2005-12-28 2007-07-12 Neurovista Corporation Methods and systems for recommending an action to a patient for managing epilepsy and other neurological disorders
BRPI0707518A2 (pt) 2006-02-06 2011-05-10 Novartis Ag combinaÇço de compostos orgÂnicos
DE102006030113B4 (de) 2006-06-28 2009-02-12 Chemische Fabrik Budenheim Kg Graphitfreier Hochtemperatur-Schmierstoff
US8039468B2 (en) 2006-08-31 2011-10-18 The Governors Of The University Of Alberta Method of inhibition of respiratory depression using positive allosteric AMPA receptor modulators
EP2115540A4 (en) 2007-01-31 2011-02-02 Quintiles Transnat Corp Inc METHOD AND SYSTEMS FOR ASSIGNING REPRESENTATIVE ELEMENTS TO LOCATIONS IN CLINICAL ATTEMPTS
EP2139467B1 (en) 2007-02-08 2016-09-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
WO2008104524A1 (en) 2007-02-28 2008-09-04 Smithkline Beecham Corporation Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
JP2011529923A (ja) 2008-08-06 2011-12-15 ゴスフォース センター(ホールディングス)プロプライエタリー リミテッド 精神障害(psychiatricdisorder)を治療するための組成物および方法
WO2010020585A1 (en) 2008-08-18 2010-02-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Serotonin reuptake inhibitors for the treatment of rett syndrome
HUE043278T2 (hu) 2008-09-05 2019-08-28 Gruenenthal Gmbh 3-(3-dimetilamino-1-etil-2-metil-propil)-fenolt és pregabalint vagy gabapentint tartalmazó gyógyszerkombináció
US8386274B1 (en) 2008-09-17 2013-02-26 Mckesson Financial Holdings Limited Systems and methods for a prescription safety network utilizing eligibility verification transactions
MX2011003695A (es) 2008-10-09 2011-08-17 A F S P A Aziende Chimiche Riunite Angelini Francesco A C R Formulacion farmaceutica liquida con contenido de paracetamol.
EP2355818A4 (en) 2008-10-10 2012-04-11 Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res METHOD AND COMPOSITIONS FOR TREATING THE STATUS EPILEPTICUS AND STATUS EPILEPTICUS CAUSING ATTACHMENTS
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
WO2010104841A2 (en) 2009-03-09 2010-09-16 Celgene Corporation Device for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated and methods for use thereof
AU2010236404B2 (en) 2009-04-15 2016-11-03 Research Triangle Institute Monoamine reuptake inhibitors
WO2010124137A1 (en) 2009-04-22 2010-10-28 Millennium Pharmacy Systems, Inc. Pharmacy management and administration with bedside real-time medical event data collection
US9453027B2 (en) 2009-07-27 2016-09-27 Daljit Singh Dhanoa Deuterium-enriched pyridinonecarboxamides and derivatives
US20110212171A1 (en) 2010-01-08 2011-09-01 Eurand, Inc. Taste masked topiramate composition and an orally disintegrating tablet comprising the same
EP3255574A1 (en) 2010-03-09 2017-12-13 Perceptimed, Inc. Medication verification and dispensing
WO2011119227A2 (en) 2010-03-25 2011-09-29 Columbia Northwest Pharmaceuticals, Llc Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients
JP2011221623A (ja) 2010-04-06 2011-11-04 Kakimori Suri 在宅診療支援システム及び方法
JP2013526583A (ja) 2010-05-21 2013-06-24 リサーチ・トライアングル・インスティチュート フェニルモルホリンおよびその類似体
EP2399513B1 (en) 2010-06-23 2017-01-04 Qatar University Qstp-B System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms
CA2805760A1 (en) 2010-07-30 2012-02-02 Merck Sharp & Dohme Corp. Inhibition of cyp3a drug metabolism
KR20180118801A (ko) 2010-09-01 2018-10-31 에자이 알앤드디 매니지먼트 가부시키가이샤 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
KR20160017668A (ko) 2010-10-26 2016-02-16 알파마 파머슈티컬스 엘엘씨 오피오이드 과다투여에 의해 유도된 호흡 저하를 약화시키기 위한 제제 및 방법
RU103209U1 (ru) 2010-10-29 2011-03-27 Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" Клиническая информационная система
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
JP5693325B2 (ja) 2011-03-29 2015-04-01 小林クリエイト株式会社 健診結果出力システム及び健診結果出力プログラム
GB201111712D0 (en) * 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
US20140348966A1 (en) 2011-12-22 2014-11-27 Onesmo B. Balemba Garcinia buchananii baker compounds, compositions and related methods
WO2013122897A1 (en) 2012-02-13 2013-08-22 Amgen Inc. Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors
US20130218586A1 (en) 2012-02-21 2013-08-22 Frederic J. Huser Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status
JP6075973B2 (ja) 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
SG11201503505QA (en) 2012-11-15 2015-06-29 Galleon Pharmaceuticals Inc Novel orally bioavailable breathing control modulating compounds, and methods of using same
WO2014106825A2 (en) 2013-01-06 2014-07-10 Jonathan Rabinowitz Methods and devices for identifying improper medical reporting
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
EP3636264A1 (en) 2013-08-19 2020-04-15 The Regents of the University of California Compounds and methods for treating an epileptic disorder
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US20150141415A1 (en) 2013-11-20 2015-05-21 Omonike Arike Olaleye Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases
CN103886415A (zh) 2014-03-25 2014-06-25 北京蝶禾谊安信息技术有限公司 药品管理方法和装置
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
MX378188B (es) 2014-09-29 2025-03-10 Zogenix International Ltd Sistema de control para el control de distribucion de medicacion.
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
IL252848B2 (en) 2015-02-06 2024-07-01 Marinus Pharmaceuticals Inc Intravenous Genaxolone Formulations and Their Use in the Treatment of Epileptic Seizures and Other Seizure Disorders
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
JP6668045B2 (ja) 2015-05-15 2020-03-18 ゾゲニクス インターナショナル リミテッド ドラベ症候群を処置するための選択的5−ht受容体アゴニストおよびアンタゴニスト
CN107847512A (zh) 2015-06-17 2018-03-27 纽约市哥伦比亚大学理事会 用于包括线粒体dna耗竭综合症在内的由不平衡的核苷酸库引起的疾病的脱氧核苷疗法
EP3316890B1 (en) 2015-06-30 2023-09-06 Neurad Ltd. Novel breathing control modulating compounds, and methods of making and using same
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
EP3340971B1 (en) 2015-08-24 2024-03-13 Zogenix International Limited Methods of treating lennox-gastaut syndrome using fenfluramine
US20220193082A1 (en) 2015-09-14 2022-06-23 Zogenix International Limited Combination treatment of specific forms of epilepsy
US20170071949A1 (en) 2015-09-14 2017-03-16 Zogenix International Limited Combination treatment of specific forms of epilepsy
EP3170807B1 (en) 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
HUE053114T2 (hu) 2015-12-22 2021-06-28 Zogenix International Ltd Fenfluramin kompozíciók és eljárások azok elõállítására
WO2017112701A1 (en) * 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP6753418B2 (ja) 2016-01-14 2020-09-09 Agc株式会社 フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品
WO2018037306A1 (en) 2016-08-24 2018-03-01 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
US20190083425A1 (en) 2016-08-24 2019-03-21 Zogenix International Limited Formulation for inhibiting formation of 5-ht2b agonists and methods of using same
US20180092864A1 (en) 2016-09-30 2018-04-05 Zogenix International Limited Compositions and methods for treating seizure disorders
EP3634392A1 (en) 2017-05-09 2020-04-15 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
US20190091179A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
WO2019067413A1 (en) 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US20190247333A1 (en) 2017-09-26 2019-08-15 Zogenix International Limited Method of reduction in convulsive seizure frequency
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US20190091176A1 (en) 2017-09-26 2019-03-28 Zogenix International Limited Method of treating selected patient population experiencing dravet syndrome
US11352882B2 (en) 2018-03-12 2022-06-07 Cameron International Corporation Plug assembly for a mineral extraction system
JP7769355B2 (ja) 2018-04-18 2025-11-13 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ミトコンドリアdna枯渇症候群を含む不均衡ヌクレオチドプールに起因する疾患の遺伝子治療
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
JP2021530481A (ja) 2018-07-10 2021-11-11 ゾゲニクス インターナショナル リミテッド 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン
KR20210061332A (ko) 2018-07-27 2021-05-27 제논 파마슈티칼스 인크. 뇌전증 치료 방법
SG11202104378SA (en) 2018-11-19 2021-05-28 Zogenix International Ltd Methods of treating rett syndrome using fenfluramine
EP3887481A4 (en) 2018-11-30 2022-08-03 Zogenix International Limited METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS
JP2022521446A (ja) 2019-02-25 2022-04-07 ゾゲニクス インターナショナル リミテッド 発作制御を改善するための製剤
US20210299064A1 (en) 2020-02-05 2021-09-30 Zogenix International Limited Method of treating patients with lennox-gastaut syndrome
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine

Similar Documents

Publication Publication Date Title
JP2019507111A5 (enExample)
CN113365998A (zh) 用于parp抑制剂的吲哚并七元酰肟类似物
JP2016503797A5 (enExample)
JP2019516739A5 (enExample)
RU2487124C2 (ru) Новое амидное производное и его использование в качестве лекарственного средства
JP2016518437A5 (enExample)
JP2014500295A5 (enExample)
JP2014506907A5 (enExample)
JP2012519691A5 (enExample)
JP2013532652A5 (enExample)
JP2011518835A5 (enExample)
JP2015514808A5 (enExample)
JP2016503800A5 (enExample)
JP2016513130A5 (enExample)
JP2015504081A5 (enExample)
JP2020511536A5 (enExample)
JP2015516427A5 (enExample)
JP2019505529A5 (enExample)
JP2019535723A5 (enExample)
JP2019520344A5 (enExample)
JP2014532730A5 (ja) オピオイド受容体の調節物質およびそれを含む薬学的組成物
JP2019529460A5 (enExample)
JP2017532294A5 (enExample)
JP2018529737A5 (enExample)
JP2011518168A5 (enExample)